PMID- 18156371
OWN - NLM
STAT- MEDLINE
DCOM- 20080118
LR  - 20181201
IS  - 1468-2079 (Electronic)
IS  - 0007-1161 (Linking)
VI  - 92
IP  - 1
DP  - 2008 Jan
TI  - The efficacy and harm of prostaglandin analogues for IOP reduction in glaucoma 
      patients compared to dorzolamide and brimonidine: a systematic review.
PG  - 7-12
AB  - AIM: To systematically review the literature on the efficacy and harm of 
      prostaglandin analogues (PGAs) compared to brimonidine and dorzolamide in 
      treating elevated intraocular pressure (IOP). METHODS: Keywords were searched in 
      major literature databases to identify relevant randomised clinical trials (RCTs) 
      of PGAs for ophthalmic use. The study quality of RCTs was assessed using the 
      Jadad scale. Outcomes assessed included reduction in IOP in individual patients, 
      adverse events (AEs) and withdrawals due to AEs. RESULTS: Eight unique RCTs 
      evaluating a total of 1,722 individuals were included in this systematic review. 
      Analysis did not show a significant reduction in the mean IOP from patients 
      receiving latanoprost compared with those receiving brimonidine (WMD = -1.04; p = 
      0.30). On the other hand, the latanoprost group showed a significant reduction in 
      mean IOP compared to the dorzolamide group (WMD = -2.64; p<0.00001). The number 
      of ocular AEs (excluding hyperaemia) was significantly higher in the brimonidine 
      group compared with the latanoprost group (RR = 0.66; p = 0.0005). CONCLUSION: 
      Latanoprost was found to be significantly superior to dorzolamide but not 
      brimonidine. However, ocular adverse events were significantly fewer in 
      latanoprost users than in brimonide users. Neither travoprost nor bimatoprost was 
      compared to dorzolamide or brimonidine in the present literature.
FAU - Hodge, W G
AU  - Hodge WG
AD  - University of Ottawa Eye Institute, The Ottawa Hospital General Campus, 501 Smyth 
      Road, Tower III, Ottawa Ontario, K1H 8L6, Canada. whodge@ottawahospital.on.ca
FAU - Lachaine, J
AU  - Lachaine J
FAU - Steffensen, I
AU  - Steffensen I
FAU - Murray, C
AU  - Murray C
FAU - Barnes, D
AU  - Barnes D
FAU - Foerster, V
AU  - Foerster V
FAU - Ducruet, T
AU  - Ducruet T
FAU - Morrison, A
AU  - Morrison A
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
PL  - England
TA  - Br J Ophthalmol
JT  - The British journal of ophthalmology
JID - 0421041
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Prostaglandins F, Synthetic)
RN  - 0 (Prostaglandins, Synthetic)
RN  - 0 (Quinoxalines)
RN  - 0 (Sulfonamides)
RN  - 0 (Thiophenes)
RN  - 4S9CL2DY2H (Brimonidine Tartrate)
RN  - 6Z5B6HVF6O (Latanoprost)
RN  - 9JDX055TW1 (dorzolamide)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antihypertensive Agents/adverse effects/*therapeutic use
MH  - Brimonidine Tartrate
MH  - Female
MH  - Glaucoma/*drug therapy
MH  - Humans
MH  - Latanoprost
MH  - Male
MH  - Middle Aged
MH  - Prostaglandins F, Synthetic/adverse effects/therapeutic use
MH  - Prostaglandins, Synthetic/adverse effects/*therapeutic use
MH  - Quinoxalines/therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Sulfonamides/therapeutic use
MH  - Thiophenes/therapeutic use
MH  - Treatment Outcome
RF  - 36
EDAT- 2007/12/25 09:00
MHDA- 2008/01/19 09:00
CRDT- 2007/12/25 09:00
PHST- 2007/12/25 09:00 [pubmed]
PHST- 2008/01/19 09:00 [medline]
PHST- 2007/12/25 09:00 [entrez]
AID - 92/1/7 [pii]
AID - 10.1136/bjo.2007.123737 [doi]
PST - ppublish
SO  - Br J Ophthalmol. 2008 Jan;92(1):7-12. doi: 10.1136/bjo.2007.123737.